StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

Stock analysts at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Up 14.2 %

OPGN stock opened at $1.37 on Thursday. OpGen has a fifty-two week low of $0.53 and a fifty-two week high of $9.90. The firm’s 50-day simple moving average is $1.02 and its 200 day simple moving average is $1.61.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.